Irena Mlinaric-Rascan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5965182/publications.pdf

Version: 2024-02-01

567144 580701 39 676 15 25 citations g-index h-index papers 39 39 39 1055 docs citations times ranked citing authors all docs

#	Article	lF	CITATIONS
1	The Enhanced Cytotoxic Effects in B-Cell Leukemia and Lymphoma Following Activation of Prostaglandin EP4 Receptor and Targeting of CD20 Antigen by Monoclonal Antibodies. International Journal of Molecular Sciences, 2022, 23, 1599.	1.8	O
2	A Common Polymorphism in the MTHFD1 Gene Is a Modulator of Risk of Congenital Heart Disease. Journal of Cardiovascular Development and Disease, 2022, 9, 166.	0.8	1
3	EP4 receptor agonist L-902688 augments cytotoxic activities of ibrutinib, idelalisib, and venetoclax against chronic lymphocytic leukemia cells. Biochemical Pharmacology, 2021, 183, 114352.	2.0	3
4	Structural Fine-Tuning of Desmuramylpeptide NOD2 Agonists Defines Their <i>In Vivo</i> Adjuvant Activity. Journal of Medicinal Chemistry, 2021, 64, 7809-7838.	2.9	12
5	Polymorphisms in GNMT and DNMT3b are associated with methotrexate treatment outcome in plaque psoriasis. Biomedicine and Pharmacotherapy, 2021, 138, 111456.	2.5	13
6	Targeting Autophagy Triggers Apoptosis and Complements the Action of Venetoclax in Chronic Lymphocytic Leukemia Cells. Cancers, 2021, 13, 4557.	1.7	12
7	Polymorphism in Gene for ABCC2 Transporter Predicts Methotrexate Drug Survival in Patients with Psoriasis. Medicina (Lithuania), 2021, 57, 1050.	0.8	3
8	Robust Saliva-Based RNA Extraction-Free One-Step Nucleic Acid Amplification Test for Mass SARS-CoV-2 Monitoring. Molecules, 2021, 26, 6617.	1.7	8
9	ATG12 deficiency leads to tumor cell oncosis owing to diminished mitochondrial biogenesis and reduced cellular bioenergetics. Cell Death and Differentiation, 2020, 27, 1965-1980.	5.0	20
10	Simultaneous quantification of intracellular concentrations of clinically important metabolites of folate-homocysteine cycle by LC-MS/MS. Analytical Biochemistry, 2020, 605, 113830.	1.1	6
11	Folate Insufficiency Due to MTHFR Deficiency Is Bypassed by 5-Methyltetrahydrofolate. Journal of Clinical Medicine, 2020, 9, 2836.	1.0	20
12	Structural features and functional activities of benzimidazoles as NOD2 antagonists. European Journal of Medicinal Chemistry, 2020, 190, 112089.	2.6	7
13	A Putative Serine Protease is Required to Initiate the RIPK3-MLKL—Mediated Necroptotic Death Pathway in Neutrophils. Frontiers in Pharmacology, 2020, 11, 614928.	1.6	5
14	Methylation of selenocysteine catalysed by thiopurine S-methyltransferase. Biochimica Et Biophysica Acta - General Subjects, 2019, 1863, 182-190.	1.1	13
15	Harnessing the untapped potential of nucleotideâ€binding oligomerization domain ligands for cancer immunotherapy. Medicinal Research Reviews, 2019, 39, 1447-1484.	5.0	27
16	Farmakogenetski oznaÄevalci v terapiji akutne limfoblastne levkemije pri otrocih. ZdravniÅįki Vestnik, 2019, 88, 235-248.	0.1	0
17	Discovery of Nanomolar Desmuramylpeptide Agonists of the Innate Immune Receptor Nucleotide-Binding Oligomerization Domain-Containing Protein 2 (NOD2) Possessing Immunostimulatory Properties. Journal of Medicinal Chemistry, 2018, 61, 2707-2724.	2.9	27
18	Novel motif of variable number of tandem repeats in <i>TPMT</i> Âpromoter region and evolutionary association of variable number of tandem repeats with <i>TPMT*3</i> Âalleles. Pharmacogenomics, 2018, 19, 1311-1322.	0.6	10

#	Article	IF	CITATIONS
19	Endocrine disrupting activities and immunomodulatory effects in lymphoblastoid cell lines of diclofenac, 4-hydroxydiclofenac and paracetamol. Toxicology Letters, 2018, 294, 95-104.	0.4	16
20	Repositioning Drugs for Rare Immune Diseases: Hopes and Challenges for a Precision Medicine. Current Medicinal Chemistry, 2018, 25, 2764-2782.	1.2	7
21	Structural features of subtype-selective EP receptor modulators. Drug Discovery Today, 2017, 22, 57-71.	3.2	126
22	PACSIN2 polymorphism is associated with thiopurine-induced hematological toxicity in children with acute lymphoblastic leukaemia undergoing maintenance therapy. Scientific Reports, 2016, 6, 30244.	1.6	22
23	Structural requirements of acylated Gly- l -Ala- d -Glu analogs for activation of the innate immune receptor NOD2. European Journal of Medicinal Chemistry, 2016, 116, 1-12.	2.6	23
24	Identification of indole scaffold-based dual inhibitors of NOD1 and NOD2. Bioorganic and Medicinal Chemistry, 2016, 24, 5221-5234.	1.4	16
25	Risk factors for symptomatic osteonecrosis in childhood ALL: A retrospective study of a Slovenian pediatric ALL population between 1970 and 2004. Experimental and Therapeutic Medicine, 2016, 12, 840-846.	0.8	2
26	Nonpeptidic Selective Inhibitors of the Chymotrypsin‣ike (β5 i) Subunit of the Immunoproteasome. Angewandte Chemie, 2016, 128, 5839-5842.	1.6	3
27	Nonpeptidic Selective Inhibitors of the Chymotrypsin‣ike (β5 i) Subunit of the Immunoproteasome. Angewandte Chemie - International Edition, 2016, 55, 5745-5748.	7.2	38
28	Characterization of human lymphoblastoid cell lines as a novel in vitro test system to predict the immunotoxicity of xenobiotics. Toxicology Letters, 2015, 233, 8-15.	0.4	13
29	Antioxidant and anti-inflammatory properties of 1,2,4-oxadiazole analogs of resveratrol. Chemico-Biological Interactions, 2015, 240, 200-207.	1.7	39
30	Association of ITPA Genotype with Event-Free Survival and Relapse Rates in Children with Acute Lymphoblastic Leukemia Undergoing Maintenance Therapy. PLoS ONE, 2014, 9, e109551.	1.1	11
31	Chemo-sensitizing effects of EP4 receptor-induced inactivation of nuclear factor-l̂ºB. European Journal of Pharmacology, 2014, 742, 81-88.	1.7	11
32	Discovery of Novel Small-Molecule Compounds with Selective Cytotoxicity for Burkitt's Lymphoma Cells Using 3D Ligand-Based Virtual Screening. Molecules, 2014, 19, 19209-19219.	1.7	0
33	Synthesis of conformationally constrained \hat{l}^3 -d-glutamyl-meso-diaminopimelic acid derivatives as ligands of nucleotide-binding oligomerization domain protein 1 (Nod1). European Journal of Medicinal Chemistry, 2013, 69, 232-243.	2.6	27
34	Immunomodulatory Properties of Novel Nucleotide Oligomerization Domain 2 (Nod2) Agonistic Desmuramyldipeptides. Journal of Medicinal Chemistry, 2012, 55, 6478-6488.	2.9	31
35	EP4 receptor signalling in immature B cells involves cAMP and NF- <i>\hat{I}°</i> B dependent pathways. Journal of Pharmacy and Pharmacology, 2012, 64, 1090-1098.	1.2	18
36	Prostaglandin EP4 receptor enhances BCR-induced apoptosis of immature B cells. Prostaglandins and Other Lipid Mediators, 2011, 95, 19-26.	1.0	23

3

#	Article	IF	CITATIONS
37	Design, synthesis and biological evaluation of novel desmuramyldipeptide analogs. European Journal of Medicinal Chemistry, 2011, 46, 3762-3777.	2.6	24
38	A Myc-regulated transcriptional network controls B-cell fate in response to BCR triggering. BMC Genomics, 2009, 10, 323.	1.2	26
39	B cell receptor-mediated nuclear fragmentation proceeds in WEHI 231 cells in the absence of detectable DEVDase and FRase activity. FEBS Letters, 2003, 553, 51-55.	1.3	13